The stock of BioCardia Inc. (BCDA) has seen a 84.85% increase in the past week, with a 84.37% gain in the past month, and a -16.66% decrease in the past quarter. The volatility ratio for the week is 30.21%, and the volatility levels for the past 30 days are at 12.77% for BCDA. The simple moving average for the past 20 days is 51.75% for BCDA’s stock, with a -52.16% simple moving average for the past 200 days.
Is It Worth Investing in BioCardia Inc. (NASDAQ: BCDA) Right Now?
Additionally, the 36-month beta value for BCDA is 1.71. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The average price predicted by analysts for BCDA is $4.00, which is $3.28 above the current price. The public float for BCDA is 10.05M and currently, short sellers hold a 1.32% ratio of that float. The average trading volume of BCDA on November 20, 2023 was 2.38M shares.
BCDA) stock’s latest price update
BioCardia Inc. (NASDAQ: BCDA)’s stock price has dropped by -9.97 in relation to previous closing price of 0.80. Nevertheless, the company has seen a gain of 84.85% in its stock price over the last five trading days. Zacks Investment Research reported 2023-11-15 that The FDA approves BioCardia’s (BCDA) phase III study on its CardiAMP cell therapy to treat patients with ischemic heart failure.
BCDA Trading at 64.82% from the 50-Day Moving Average
After a stumble in the market that brought BCDA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.31% of loss for the given period.
Volatility was left at 12.77%, however, over the last 30 days, the volatility rate increased by 30.21%, as shares surge +85.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +56.65% upper at present.
During the last 5 trading sessions, BCDA rose by +84.85%, which changed the moving average for the period of 200-days by -69.71% in comparison to the 20-day moving average, which settled at $0.4916. In addition, BioCardia Inc. saw -65.51% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at BCDA starting from Altman Peter, who purchase 6,200 shares at the price of $1.60 back on May 26. After this action, Altman Peter now owns 469,239 shares of BioCardia Inc., valued at $9,920 using the latest closing price.
FROST PHILLIP MD ET AL, the 10% Owner of BioCardia Inc., purchase 595,238 shares at $1.68 during a trade that took place back on Dec 16, which means that FROST PHILLIP MD ET AL is holding 2,025,827 shares at $1,000,000 based on the most recent closing price.
Stock Fundamentals for BCDA
Current profitability levels for the company are sitting at:
- -880.25 for the present operating margin
- +72.12 for the gross margin
The net margin for BioCardia Inc. stands at -880.70. The total capital return value is set at -126.84, while invested capital returns managed to touch -130.75. Equity return is now at value -728.95, with -193.83 for asset returns.
Based on BioCardia Inc. (BCDA), the company’s capital structure generated 33.34 points at debt to equity in total, while total debt to capital is 25.00. Total debt to assets is 16.65, with long-term debt to equity ratio resting at 26.90. Finally, the long-term debt to capital ratio is 20.17.
When we switch over and look at the enterprise to sales, we see a ratio of 17.29, with the company’s debt to enterprise value settled at 0.05. The receivables turnover for the company is 7.77 and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.19.
In conclusion, BioCardia Inc. (BCDA) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.